Clinical Scorecard: Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema

At a Glance

Key Highlights

• Benvitimod shows similar efficacy to halometasone in treating moderate-to-severe CHE.
• Benvitimod demonstrates a more favorable safety and tolerability profile compared to halometasone.
• Topical corticosteroids have limited evidence for long-term effectiveness and are often refused by patients due to side effects.

Guideline-Based Recommendations

Diagnosis

• Classify CHE severity using Physician Global Assessment (PGA).
• Exclude other skin disorders and infections before diagnosis.

Management

• Use topical corticosteroids as primary treatment for mild-to-moderate CHE.
• Consider benvitimod cream as an alternative topical treatment for moderate-to-severe CHE.
• Avoid concurrent use of other effective CHE treatments during therapy.
• Apply moisturizer daily and avoid irritants/allergens.

Monitoring & Follow-up

• Assess treatment response at weeks 4, 8, and 12 using PGA scores.
• Define treatment success as 'clear' or 'almost clear' with ≥2-point PGA improvement.
• Monitor for relapse up to 24 weeks post-treatment success without additional CHE therapies.

Risks

• Potential side effects and high relapse rates with long-term topical corticosteroid use.
• Limited evidence for corticosteroid efficacy in severe CHE; 2-4% may be refractory.
• Benvitimod may offer improved safety but requires monitoring for adverse reactions.

Patient & Prescribing Data

Adults with moderate-to-severe chronic hand eczema refractory or intolerant to corticosteroids

Benvitimod cream administered twice daily for 8 weeks is effective and better tolerated than halometasone cream.

Clinical Best Practices

• Obtain informed consent and ensure ethical compliance before treatment initiation.
• Screen patients carefully to exclude infections, allergies, and other skin conditions.
• Use standardized severity assessments (PGA) to guide treatment decisions and monitor progress.
• Educate patients on the importance of moisturizer use and avoidance of irritants.
• Consider benvitimod as a nonsteroidal alternative for patients unwilling or unable to use corticosteroids.
• Allow patient withdrawal from treatment if severe adverse events occur.

References

• Clinical trial registration ChiCTR2100051948